• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Right Arrow Button IconLeft Arrow Button IconHome
Right Arrow Button IconBiosimilars

Biosimilars

An Amgen sign is seen at the company's office in South San Francisco
HealthAmgen Is Taking On a $3 Billion Cancer Drug. But Will It Cut Costs for Patients?
By Sy MukherjeeSeptember 15, 2017
Trading On The Floor Of The NYSE As U.S. Stocks Rise Amid Stronger Job Gains Boost Optimism On Economy
HealthThis Biotech’s Stock Plunged 24% After the FDA Rejected Its Amgen Drug Copycat
By Sy MukherjeeJune 12, 2017
CA: Companies In California
HealthThe World’s Best-Selling Drug Just Lost a Key Patent Battle
By Sy MukherjeeMay 18, 2017
HealthFDA Approves New Drug That Could Take a Slice Out of Johnson & Johnson’s Best Seller
By Sy MukherjeeApril 24, 2017
Drugs From European Pharmaceuticals Companies As Stocks Outperformed The Stoxx 600 Index By 1.2 percentage Points
HealthWhy These Copycat Drugs Aren’t Slashing Best-Sellers’ Prices
By Sy MukherjeeOctober 18, 2016
The Davos World Economic Forum 2015
HealthNovartis Just Got Some Great News in Its Battle for Amgen’s Market Share
By Sy MukherjeeAugust 31, 2016
The Davos World Economic Forum 2015
HealthAmgen Finally Scores a Win in Its Big Copycat Drug Battle With Novartis
By Sy MukherjeeJuly 19, 2016
Close up of surgical tools and money
HealthTwo of the World’s Best-Selling Drugs Are Headed for a Lot More Competition
By Sy MukherjeeJuly 15, 2016
HealthWhy a Bipartisan Bill Is Pitting the Biopharma Industry Against Itself
By Sy MukherjeeJune 27, 2016
Herceptin Approved For Treatment Of Scottish Breast Cancer Patients
HealthHow Mylan Is Taking On One of the World’s Top Breast Cancer Drugs
By Sy MukherjeeJune 5, 2016
Samsung Holds Shareholders Meeting
TechSamsung Has a Best-Selling American Drug in Its Crosshairs
By Sy MukherjeeMay 24, 2016
A screen displays the share price for pharmaceutical maker AbbVie on the floor of the New York Stock Exchange
HealthSamsung’s Drug Group Is Taking AbbVie to Court in Biotech Copycat Push
By ReutersApril 4, 2016
HealthThe U.S. and Europe Could Save $110 Billion With Copycat Biotech Drugs
By ReutersMarch 29, 2016
Exclusive Look At Pharmaceuticals Manufacturing Inside Lupin Ltd. Facility, India's Third-Largest Drugmaker
FinanceIndian Companies Want to Sell U.S. Customers More Drugs
By Laura LorenzettiFebruary 25, 2016
HealthBiosimilars Are Coming After Big Pharma’s Bottom Line
By Laura LorenzettiJanuary 12, 2016
1
  • 1
  • 2
2
Most Popular
Magazine
The youngest-ever female CEO of a Fortune 500 company is fighting Trump's cuts to keep Medicaid strongAn image of a popular article
By Fortune EditorsMarch 24, 2026
Commentary
The Treasury just declared the U.S. insolvent. The media missed itAn image of a popular article
By Fortune EditorsMarch 23, 2026
Success
Palantir’s billionaire CEO says only two kinds of people will succeed in the AI era: trade workers — ‘or you’re neurodivergent’An image of a popular article
By Fortune EditorsMarch 24, 2026
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.